Bevantolol
From Wikipedia, the free encyclopedia
 |
|
| Systematic (IUPAC) name | |
|---|---|
|
(RS)-[2-(3,4-dimethoxyphenyl)ethyl][2-hydroxy-3-(3-methylphenoxy)propyl]amine
|
|
| Clinical data | |
| AHFS/Drugs.com | International Drug Names |
| Legal status |
|
| Routes of administration |
Oral |
| Identifiers | |
| CAS Number | 59170-23-9  |
| ATC code | C07AB06 |
| PubChem | CID: 2372 |
| DrugBank | DB01295 |
| ChemSpider | 2282 |
| UNII | 34ZXW6ZV21 |
| ChEBI | CHEBI:238698 |
| ChEMBL | CHEMBL314010 |
| Chemical data | |
| Formula | C20H27NO4 |
| Molecular mass | 345.43 g/mol |
|
|
|
|
| (verify) |
Bevantolol (INN) is a drug that acts as both a beta blocker and a calcium channel blocker.[1]
References[edit]
- ^ Warltier DC, Gross GJ, Jesmok GJ, Brooks HL, Hardman HF (1980). "Protection of Ischemic Myocardium: Comparison of Effects of Propranolol, Bevantolol and N-Dimethyl Propranolol on Infarct Size Following Coronary Artery Occlusion in Anesthetized Dogs". Cardiology 66.
|
 |
This article about an amine is a stub. You can help Wikipedia by expanding it. |
 |
This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |
